{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T19:55:47Z","timestamp":1782849347392,"version":"3.54.5"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:00:00Z","timestamp":1779926400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:00:00Z","timestamp":1779926400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s12185-026-04229-8","type":"journal-article","created":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T08:35:23Z","timestamp":1779957323000},"page":"19-30","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical implications of minimal residual disease monitoring in multiple myeloma"],"prefix":"10.1007","volume":"124","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-1575-1343","authenticated-orcid":false,"given":"Takeshi","family":"Yoroidaka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,28]]},"reference":[{"key":"4229_CR1","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1038\/s41588-024-01853-0","volume":"56","author":"S Skerget","year":"2024","unstructured":"Skerget S, Penaherrera D, Chari A, Jagannath S, Siegel DS, Vij R, et al. Comprehensive molecular profiling of multiple myeloma identifies refined copy number and expression subtypes. Nat Genet. 2024;56:1878\u201389.","journal-title":"Nat Genet"},{"key":"4229_CR2","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1200\/JCO.23.01277","volume":"42","author":"F Maura","year":"2024","unstructured":"Maura F, Rajanna AR, Ziccheddu B, Poos AM, Derkach A, Maclachlan K, et al. Genomic classification and individualized prognosis in multiple myeloma. J Clin Oncol. 2024;42:1229\u201340.","journal-title":"J Clin Oncol"},{"key":"4229_CR3","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1002\/ajh.27422","volume":"99","author":"SV Rajkumar","year":"2024","unstructured":"Rajkumar SV. Multiple myeloma: 2024 update on diagnosis, risk\u2010stratification, and management. Am J Hematol. 2024;99:1802\u201324.","journal-title":"Am J Hematol"},{"key":"4229_CR4","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024015685","author":"BA Derman.","year":"2025","unstructured":"Derman. BA, Yee. AJ. Clinical applications of mass spectrometry in multiple myeloma. Blood Adv. 2025. https:\/\/doi.org\/10.1182\/bloodadvances.2024015685. (Online ahead of print).","journal-title":"Blood Adv"},{"key":"4229_CR5","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1182\/blood.2025029234","volume":"146","author":"M Lasa","year":"2025","unstructured":"Lasa M, Gonzalez C, Notarfranchi L, Zherniakova A, Alignani D, Burgos L, et al. Ultrasensitive detection of circulating multiple myeloma cells by next-generation flow after immunomagnetic enrichment. Blood. 2025;146:964\u201370.","journal-title":"Blood"},{"key":"4229_CR6","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17:e328\u201346.","journal-title":"Lancet Oncol"},{"key":"4229_CR7","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1158\/2643-3230.BCD-24-0292","volume":"6","author":"O Landgren","year":"2025","unstructured":"Landgren O, Devlin SM. Minimal residual disease as an early endpoint for accelerated drug approval in myeloma: A roadmap. Blood Cancer Discov. 2025;6:13\u201322.","journal-title":"Blood Cancer Discov"},{"key":"4229_CR8","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1182\/blood.2024026230","volume":"146","author":"A Perrot","year":"2025","unstructured":"Perrot A, Touzeau C, Lambert J, Hulin C, Caillot D, Karlin L, et al. Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone induction in newly diagnosed myeloma: analysis of the MIDAS Trial. Blood. 2025;146:52\u201361.","journal-title":"Blood"},{"key":"4229_CR9","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1182\/blood.2024027674","volume":"146","author":"S Giri","year":"2025","unstructured":"Giri S, Dhakal B, Callander NS, Medvedova E, Godby K, Dholaria B, et al. Optimal MRD-based end point to support response-adapted treatment cessation in newly diagnosed multiple myeloma. Blood. 2025;146:707\u201316.","journal-title":"Blood"},{"key":"4229_CR10","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1007\/s11912-024-01537-2","volume":"26","author":"M Meseha","year":"2024","unstructured":"Meseha M, Hoffman J, Kazandjian D, Landgren O, Diamond B. Minimal residual disease-adapted therapy in multiple myeloma: current evidence and opinions. Curr Oncol Rep. 2024;26:679\u201390.","journal-title":"Curr Oncol Rep"},{"key":"4229_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01156-x","volume":"14","author":"BA Derman","year":"2024","unstructured":"Derman BA, Major A, Cooperrider J, Jiang K, Ramsland A, Karrison T, et al. Discontinuation of maintenance therapy in multiple myeloma guided by multimodal measurable residual disease negativity (MRD2STOP). Blood Cancer J. 2024;14:170.","journal-title":"Blood Cancer J"},{"key":"4229_CR12","doi-asserted-by":"publisher","first-page":"e890","DOI":"10.1016\/S2352-3026(23)00236-3","volume":"10","author":"LJ Costa","year":"2023","unstructured":"Costa LJ, Chhabra S, Medvedova E, Dholaria BR, Schmidt TM, Godby KN, et al. Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial. Lancet Haematol. 2023;10:e890\u2013901.","journal-title":"Lancet Haematol"},{"key":"4229_CR13","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1182\/blood-2014-11-568907","volume":"125","author":"B Paiva","year":"2015","unstructured":"Paiva B, van Dongen JJ, Orfao A. New criteria for response assessment: role of minimal residual disease in multiple myeloma. Blood. 2015;125:3059\u201368.","journal-title":"Blood"},{"key":"4229_CR14","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.1038\/leu.2012.120","volume":"26","author":"JJ van Dongen","year":"2012","unstructured":"van Dongen JJ, Lhermitte L, Bottcher S, Almeida J, van der Velden VH, Flores-Montero J, et al. EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia. 2012;26:1908\u201375.","journal-title":"Leukemia"},{"key":"4229_CR15","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1038\/leu.2017.29","volume":"31","author":"J Flores-Montero","year":"2017","unstructured":"Flores-Montero J, Sanoja-Flores L, Paiva B, Puig N, Garcia-Sanchez O, Bottcher S, et al. Next generation flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma. Leukemia. 2017;31:2094\u2013103.","journal-title":"Leukemia"},{"key":"4229_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-020-07077-9","volume":"20","author":"T Ching","year":"2020","unstructured":"Ching T, Duncan ME, Newman-Eerkes T, McWhorter MME, Tracy JM, Steen MS, et al. Analytical evaluation of the clonoSEQ assay for establishing measurable (minimal) residual disease in acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma. BMC Cancer. 2020;20:612.","journal-title":"BMC Cancer"},{"key":"4229_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102016","volume":"60","author":"S Oliva","year":"2023","unstructured":"Oliva S, Genuardi E, Paris L, D\u2019Agostino M, Rogers J, Rota-Scalabrini D, et al. Prospective evaluation of minimal residual disease in the phase II FORTE trial: a head-to-head comparison between multiparameter flow cytometry and next-generation sequencing. EClinicalMedicine. 2023;60:102016.","journal-title":"EClinicalMedicine"},{"key":"4229_CR18","first-page":"2160","volume":"110","author":"T Yoroidaka","year":"2025","unstructured":"Yoroidaka T, Takamatsu H, Urushihara R, Itagaki M, Yoshihara S, Sato K, et al. Prognostic value of minimal residual disease detected by EuroFlow next-generation flow cytometry and next-generation sequencing in patients with multiple myeloma achieving complete response and receiving lenalidomide maintenance after autotransplant: a prospective comparison study. Haematologica. 2025;110:2160\u201370.","journal-title":"Haematologica"},{"key":"4229_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12082322","volume":"12","author":"K Kriegsmann","year":"2020","unstructured":"Kriegsmann K, Hundemer M, Hofmeister-Mielke N, Reichert P, Manta CP, Awwad MHS, et al. Comparison of NGS and MFC methods: key metrics in multiple myeloma MRD assessment. Cancers (Basel). 2020;12:2322.","journal-title":"Cancers (Basel)"},{"key":"4229_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-025-01327-4","volume":"15","author":"C Messiou","year":"2025","unstructured":"Messiou C, Porta N, Koh DM, Riddell A, Downey K, Croft J, et al. Whole body MRI by MY-RADS for imaging response assessment in multiple myeloma. Blood Cancer J. 2025;15:122.","journal-title":"Blood Cancer J"},{"key":"4229_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102017","volume":"60","author":"E Zamagni","year":"2023","unstructured":"Zamagni E, Oliva S, Gay F, Capra A, Rota-Scalabrini D, D\u2019Agostino M, et al. Impact of minimal residual disease standardised assessment by FDG-PET\/CT in transplant-eligible patients with newly diagnosed multiple myeloma enrolled in the imaging sub-study of the FORTE trial. EClinicalMedicine. 2023;60:102017.","journal-title":"EClinicalMedicine"},{"key":"4229_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2023.101767","volume":"37","author":"TJ Wellman","year":"2023","unstructured":"Wellman TJ, Mudd SR, Godby KN, Wooten DW, Ross JA, Bueno OF, et al. Evaluation of a semi-automated approach for FDG PET image analysis for routine clinical application in patients with multiple myeloma. Transl Oncol. 2023;37:101767.","journal-title":"Transl Oncol"},{"key":"4229_CR23","doi-asserted-by":"publisher","first-page":"e302","DOI":"10.1016\/S1470-2045(19)30309-2","volume":"20","author":"J Hillengass","year":"2019","unstructured":"Hillengass J, Usmani S, Rajkumar SV, Durie BGM, Mateos MV, Lonial S, et al. International Myeloma Working Group consensus recommendations on imaging in monoclonal plasma cell disorders. Lancet Oncol. 2019;20:e302\u201312.","journal-title":"Lancet Oncol"},{"key":"4229_CR24","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1182\/bloodadvances.2023010821","volume":"8","author":"B Paiva","year":"2024","unstructured":"Paiva B, Zherniakova A, Nu\u00f1ez-C\u00f3rdoba JM, Rodriguez-Otero P, Shi Q, Munshi NC, et al. Impact of treatment effect on MRD and PFS: an aggregate data analysis from randomized clinical trials in multiple myeloma. Blood Adv. 2024;8:219\u201323.","journal-title":"Blood Adv"},{"key":"4229_CR25","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1182\/blood.2024024371","volume":"144","author":"O Landgren","year":"2024","unstructured":"Landgren O, Prior TJ, Masterson T, Heuck C, Bueno OF, Dash AB, et al. EVIDENCE meta-analysis: evaluating minimal residual disease as an intermediate clinical end point for multiple myeloma. Blood. 2024;144:359\u201367.","journal-title":"Blood"},{"key":"4229_CR26","doi-asserted-by":"publisher","first-page":"5988","DOI":"10.1182\/bloodadvances.2020002827","volume":"4","author":"NC Munshi","year":"2020","unstructured":"Munshi NC, Avet-Loiseau H, Anderson KC, Neri P, Paiva B, Samur M, et al. A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma. Blood Adv. 2020;4:5988\u201399.","journal-title":"Blood Adv"},{"key":"4229_CR27","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1002\/ajh.27582","volume":"100","author":"I Ntanasis-Stathopoulos","year":"2025","unstructured":"Ntanasis-Stathopoulos I, Filippatos C, Ntanasis-Stathopoulos A, Malandrakis P, Kastritis E, Tsitsilonis OE, et al. Evaluating Minimal Residual Disease Negativity as a Surrogate Endpoint for Treatment Efficacy in Multiple Myeloma: A Meta-Analysis of Randomized Controlled Trials. Am J Hematol. 2025;100:427\u201338.","journal-title":"Am J Hematol."},{"key":"4229_CR28","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1056\/NEJMoa2204925","volume":"387","author":"PG Richardson","year":"2022","unstructured":"Richardson PG, Jacobus SJ, Weller EA, Hassoun H, Lonial S, Raje NS, et al. Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma. N Engl J Med. 2022;387:132\u201347.","journal-title":"N Engl J Med."},{"key":"4229_CR29","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1200\/JCO.19.01231","volume":"38","author":"B Paiva","year":"2020","unstructured":"Paiva B, Puig N, Cedena MT, Rosinol L, Cordon L, Vidriales MB, et al. Measurable residual disease by next-generation flow cytometry in multiple myeloma. J Clin Oncol. 2020;38:784\u201392.","journal-title":"J Clin Oncol."},{"key":"4229_CR30","doi-asserted-by":"crossref","unstructured":"Goicoechea. I, Puig. N, Cedena. M-T, Burgos. L, \u0301on. LC, Vidriales. M\u0131-Be, et al. Deep MRD profiling defines outcome and unveils differentmodes of treatment resistance in standard- andhigh-risk myeloma. Blood. 2021; 137:49\u201360.","DOI":"10.1182\/blood.2020006731"},{"key":"4229_CR31","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-197908","volume":"144","author":"P Sonneveld","year":"2024","unstructured":"Sonneveld P, Dimopoulos MA, Beksac M, van der Holt B, Gay F, Ludwig H, et al. Consolidation treatment with VRD followed by maintenance with Lenalidomide in multiple myeloma improves overall survival: long-term follow-up of the EMN02\/HOVON95 randomized phase 3 trial. Blood. 2024;144:674.","journal-title":"Blood"},{"key":"4229_CR32","doi-asserted-by":"publisher","first-page":"3613","DOI":"10.1200\/JCO.21.01045","volume":"39","author":"P Sonneveld","year":"2021","unstructured":"Sonneveld P, Dimopoulos MA, Beksac M, van der Holt B, Aquino S, Ludwig H, et al. Consolidation and maintenance in newly diagnosed multiple myeloma. J Clin Oncol. 2021;39:3613\u201322.","journal-title":"J Clin Oncol"},{"key":"4229_CR33","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/s41408-021-00498-0","volume":"11","author":"S Oliva","year":"2021","unstructured":"Oliva S, Bruinink DHO, Rihova L, D\u2019Agostino M, Pantani L, Capra A, et al. Minimal residual disease assessment by multiparameter flow cytometry in transplant-eligible myeloma in the EMN02\/HOVON 95 MM trial. Blood Cancer J. 2021;11:106.","journal-title":"Blood Cancer J."},{"key":"4229_CR34","doi-asserted-by":"publisher","first-page":"e456","DOI":"10.1016\/S2352-3026(20)30099-5","volume":"7","author":"M Cavo","year":"2020","unstructured":"Cavo M, Gay F, Beksac M, Pantani L, Petrucci MT, Dimopoulos MA, et al. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02\/HO95): a multicentre, randomised, open-label, phase 3 study. Lancet Haematol. 2020;7:e456\u201368.","journal-title":"Lancet Haematol"},{"key":"4229_CR35","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","volume":"394","author":"P Moreau","year":"2019","unstructured":"Moreau P, Attal M, Hulin C, Arnulf B, Belhadj K, Benboubker L, et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. Lancet. 2019;394:29\u201338.","journal-title":"Lancet."},{"key":"4229_CR36","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1016\/S1470-2045(24)00282-1","volume":"25","author":"P Moreau","year":"2024","unstructured":"Moreau P, Hulin C, Perrot A, Arnulf B, Belhadj K, Benboubker L, et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial. Lancet Oncol. 2024;25:1003\u201314.","journal-title":"Lancet Oncol"},{"key":"4229_CR37","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1056\/NEJMoa2312054","volume":"390","author":"P Sonneveld","year":"2024","unstructured":"Sonneveld P, Dimopoulos MA, Boccadoro M, Quach H, Ho PJ, Beksac M, et al. Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. N Engl J Med. 2024;390:301\u201313.","journal-title":"N Engl J Med."},{"key":"4229_CR38","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1200\/JCO-24-02266","volume":"43","author":"EK Mai","year":"2025","unstructured":"Mai EK, Bertsch U, Pozek E, Fenk R, Besemer B, Hanoun C, et al. Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone induction therapy for transplant-eligible newly diagnosed multiple myeloma: final part 1 analysis of the GMMG-HD7 trial. J Clin Oncol. 2025;43:1279\u201388.","journal-title":"J Clin Oncol."},{"key":"4229_CR39","doi-asserted-by":"publisher","first-page":"e825","DOI":"10.1016\/S2352-3026(23)00217-X","volume":"10","author":"PM Voorhees","year":"2023","unstructured":"Voorhees PM, Sborov DW, Laubach J, Kaufman JL, Reeves B, Rodriguez C, et al. Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial. Lancet Haematol. 2023;10:e825\u201337.","journal-title":"Lancet Haematol"},{"key":"4229_CR40","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1182\/blood.2020010439","volume":"139","author":"J San-Miguel","year":"2022","unstructured":"San-Miguel J, Avet-Loiseau H, Paiva B, Kumar S, Dimopoulos MA, Facon T, et al. Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE. Blood. 2022;139:492\u2013501.","journal-title":"Blood."},{"key":"4229_CR41","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1038\/s41591-024-03050-2","volume":"30","author":"X Leleu","year":"2024","unstructured":"Leleu X, Hulin C, Lambert J, Bobin A, Perrot A, Karlin L, et al. Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial. Nat Med. 2024;30:2235\u201341.","journal-title":"Nat Med."},{"key":"4229_CR42","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1038\/s41591-024-03485-7","volume":"31","author":"SZ Usmani","year":"2025","unstructured":"Usmani SZ, Facon T, Hungria V, Bahlis NJ, Venner CP, Braunstein M, et al. Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial. Nat Med. 2025;31:1195\u2013202.","journal-title":"Nat Med."},{"key":"4229_CR43","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1056\/NEJMoa2400712","volume":"391","author":"T Facon","year":"2024","unstructured":"Facon T, Dimopoulos MA, Leleu XP, Beksac M, Pour L, H\u00e1jek R, et al. Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for multiple myeloma. N Engl J Med. 2024;391:1597\u2013609.","journal-title":"N Engl J Med."},{"key":"4229_CR44","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1200\/JCO.20.01814","volume":"39","author":"H Avet-Loiseau","year":"2021","unstructured":"Avet-Loiseau H, San-Miguel J, Casneuf T, Iida S, Lonial S, Usmani SZ, et al. Evaluation of sustained minimal residual disease negativity With Daratumumab-combination regimens in relapsed and\/or refractory multiple myeloma: analysis of POLLUX and CASTOR. J Clin Oncol. 2021;39:1139\u201349.","journal-title":"J Clin Oncol."},{"key":"4229_CR45","doi-asserted-by":"publisher","first-page":"3739","DOI":"10.1182\/bloodadvances.2023010026","volume":"7","author":"SZ Usmani","year":"2023","unstructured":"Usmani SZ, Quach H, Mateos MV, Landgren O, Leleu X, Siegel D, et al. Final analysis of carfilzomib, dexamethasone, and daratumumab vs carfilzomib and dexamethasone in the CANDOR study. Blood Adv. 2023;7:3739\u201348.","journal-title":"Blood Adv."},{"key":"4229_CR46","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1016\/S0140-6736(21)00592-4","volume":"397","author":"P Moreau","year":"2021","unstructured":"Moreau P, Dimopoulos M-A, Mikhael J, Yong K, Capra M, Facon T, et al. Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial. The Lancet. 2021;397:2361\u201371.","journal-title":"The Lancet."},{"key":"4229_CR47","doi-asserted-by":"crossref","unstructured":"L. A, Garfall AK, Nooka NWCJ, Donk. vd, Moreau. P, Bhutani. M, et al. Long-term follow-up from the phase 1\/2 MajesTEC-1 trial of teclistamab in patients with relapsed\/refractory multiple myeloma. J Clin Oncol. 2024; 42:7540.","DOI":"10.1200\/JCO.2024.42.16_suppl.7540"},{"key":"4229_CR48","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa2203478","volume":"387","author":"P Moreau","year":"2022","unstructured":"Moreau P, Garfall AL, van de Donk N, Nahi H, San-Miguel JF, Oriol A, et al. Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med. 2022;387:495\u2013505.","journal-title":"N Engl J Med."},{"key":"4229_CR49","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1038\/s41591-023-02589-w","volume":"29","author":"NJ Bahlis","year":"2023","unstructured":"Bahlis NJ, Costello CL, Raje NS, Levy MY, Dholaria B, Solh M, et al. Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial. Nat Med. 2023;29:2570\u20136.","journal-title":"Nat Med."},{"key":"4229_CR50","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","volume":"29","author":"AM Lesokhin","year":"2023","unstructured":"Lesokhin AM, Tomasson MH, Arnulf B, Bahlis NJ, Miles Prince H, Niesvizky R, et al. Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results. Nat Med. 2023;29:2259\u201367.","journal-title":"Nat Med."},{"key":"4229_CR51","doi-asserted-by":"publisher","first-page":"2702","DOI":"10.1200\/JCO.24.01008","volume":"42","author":"N Bumma","year":"2024","unstructured":"Bumma N, Richter J, Jagannath S, Lee HC, Hoffman JE, Suvannasankha A, et al. Linvoseltamab for treatment of relapsed\/refractory multiple myeloma. J Clin Oncol. 2024;42:2702\u201312.","journal-title":"J Clin Oncol."},{"key":"4229_CR52","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","volume":"387","author":"A Chari","year":"2022","unstructured":"Chari A, Minnema MC, Berdeja JG, Oriol A, van de Donk N, Rodriguez-Otero P, et al. Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma. N Engl J Med. 2022;387:2232\u201344.","journal-title":"N Engl J Med."},{"key":"4229_CR53","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1056\/NEJMoa2405090","volume":"391","author":"V Hungria","year":"2024","unstructured":"Hungria V, Robak P, Hus M, Zherebtsova V, Ward C, Ho PJ, et al. Belantamab Mafodotin, Bortezomib, and Dexamethasone for multiple myeloma. N Engl J Med. 2024;391:393\u2013407.","journal-title":"N Engl J Med."},{"key":"4229_CR54","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1056\/NEJMoa2403407","volume":"391","author":"MA Dimopoulos","year":"2024","unstructured":"Dimopoulos MA, Beksac M, Pour L, Delimpasi S, Vorobyev V, Quach H, et al. Belantamab Mafodotin, Pomalidomide, and Dexamethasone in multiple myeloma. N Engl J Med. 2024;391:408\u201321.","journal-title":"N Engl J Med"},{"key":"4229_CR55","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","volume":"398","author":"JG Berdeja","year":"2021","unstructured":"Berdeja JG, Madduri D, Usmani SZ, Jakubowiak A, Agha M, Cohen AD, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study. Lancet. 2021;398:314\u201324.","journal-title":"Lancet."},{"key":"4229_CR56","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1200\/JCO.22.00842","volume":"41","author":"T Martin","year":"2023","unstructured":"Martin T, Usmani SZ, Berdeja JG, Agha M, Cohen AD, Hari P, et al. Ciltacabtagene Autoleucel, an Anti-B-cell maturation antigen chimeric antigen receptor T-Cell therapy, for relapsed\/refractory multiple myeloma: CARTITUDE-1 2-year follow-up. J Clin Oncol. 2023;41:1265\u201374.","journal-title":"J Clin Oncol."},{"key":"4229_CR57","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1056\/NEJMoa2303379","volume":"389","author":"J San-Miguel","year":"2023","unstructured":"San-Miguel J, Dhakal B, Yong K, Spencer A, Anguille S, Mateos MV, et al. Cilta-cel or standard care in Lenalidomide-refractory multiple myeloma. N Engl J Med. 2023;389:335\u201347.","journal-title":"N Engl J Med"},{"key":"4229_CR58","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi NC, Anderson LD Jr., Shah N, Madduri D, Berdeja J, Lonial S, et al. Idecabtagene Vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384:705\u201316.","journal-title":"N Engl J Med"},{"key":"4229_CR59","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1158\/2643-3230.BCD-23-0044","volume":"4","author":"B Paiva","year":"2023","unstructured":"Paiva B, Manrique I, Rytlewski J, Campbell T, Kazanecki CC, Martin N, et al. Time-dependent prognostic value of serological and measurable residual disease assessments after idecabtagene vicleucel. Blood Cancer Discov. 2023;4:365\u201373.","journal-title":"Blood Cancer Discov"},{"key":"4229_CR60","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","volume":"388","author":"P Rodriguez-Otero","year":"2023","unstructured":"Rodriguez-Otero P, Ailawadhi S, Arnulf B, Patel K, Cavo M, Nooka AK, et al. Ide-cel or standard regimens in relapsed and refractory multiple myeloma. N Engl J Med. 2023;388:1002\u201314.","journal-title":"N Engl J Med."},{"key":"4229_CR61","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s13045-021-01135-w","volume":"14","author":"J Martinez-Lopez","year":"2021","unstructured":"Martinez-Lopez J, Alonso R, Wong SW, Rios R, Shah N, Ruiz-Heredia Y, et al. Making clinical decisions based on measurable residual disease improves the outcome in multiple myeloma. J Hematol Oncol. 2021;14:126.","journal-title":"J Hematol Oncol"},{"key":"4229_CR62","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1182\/bloodadvances.2024014417","volume":"9","author":"M Bhutani","year":"2025","unstructured":"Bhutani M, Robinson M, Foureau D, Atrash S, Paul B, Guo F, et al. MRD-driven phase 2 study of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma. Blood Adv. 2025;9:507\u201319.","journal-title":"Blood Adv"},{"key":"4229_CR63","doi-asserted-by":"publisher","first-page":"e890","DOI":"10.1016\/S2352-3026(23)00236-3","volume":"10","author":"LJ Costa","year":"2023","unstructured":"Costa LJ, Chhabra S, Medvedova E, Dholaria BR, Schmidt TM, Godby KN, et al. Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial. The Lancet Haematol. 2023;10:e890\u2013901.","journal-title":"The Lancet Haematol"},{"key":"4229_CR64","doi-asserted-by":"publisher","first-page":"2901","DOI":"10.1200\/JCO.21.01935","volume":"40","author":"LJ Costa","year":"2022","unstructured":"Costa LJ, Chhabra S, Medvedova E, Dholaria BR, Schmidt TM, Godby KN, et al. Daratumumab, carfilzomib, lenalidomide, and dexamethasone with minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma. J Clin Oncol. 2022;40:2901\u201312.","journal-title":"J Clin Oncol"},{"key":"4229_CR65","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01156-x","volume":"14","author":"BA Derman","year":"2024","unstructured":"Derman BA, Major A, Cooperrider J, Jiang K, Ramsland A, Karrison T, et al. Discontinuation of maintenance therapy in multiple myeloma guided by multimodal measurable residual disease negativity (MRD2STOP). Blood Cancer J. 2024;14:170.","journal-title":"Blood Cancer J"},{"key":"4229_CR66","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.1182\/blood.2024027686","volume":"145","author":"E Terpos","year":"2025","unstructured":"Terpos E, Malandrakis P, Ntanasis-Stathopoulos I, Kostopoulos IV, Eleutherakis-Papaiakovou E, Kanellias N, et al. Sustained bone marrow and imaging MRD negativity for 3 years drives discontinuation of maintenance post-ASCT in myeloma. Blood. 2025;145:2353\u201360.","journal-title":"Blood"},{"key":"4229_CR67","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1056\/NEJMoa2505133","volume":"393","author":"A Perrot","year":"2025","unstructured":"Perrot A, Lambert J, Hulin C, Pieragostini A, Karlin L, Arnulf B, et al. Measurable residual disease-guided therapy in newly diagnosed myeloma. N Engl J Med. 2025;393:425\u201337.","journal-title":"N Engl J Med"},{"key":"4229_CR68","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.7503","volume":"43","author":"CO Landgren","year":"2025","unstructured":"Landgren CO, Ye JC, Hillengass J, Sborov DW, Hoffman JE, Diamond B, et al. Randomized, multi-center study of carfilzomib, lenalidomide, and dexamethasone (KRd) with or without daratumumab (D) in patients with newly diagnosed multiple myeloma (NDMM): the ADVANCE clinical trial. J Clin Oncol. 2025;43:7503.","journal-title":"J Clin Oncol"},{"key":"4229_CR69","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-202079","volume":"144","author":"O Landgren","year":"2024","unstructured":"Landgren O, Kazandjian D. Advance multicenter clinical trial: MRD-driven therapy in newly diagnosed multiple myeloma patients. Blood. 2024;144:7035.","journal-title":"Blood"},{"key":"4229_CR70","doi-asserted-by":"crossref","unstructured":"Dhakal. B, Silbermann. R, Schmidt. TM, Medvedova. E, Bal. S, Giri. S, et al. MRD-guided sequential therapy for deep response in newly diagnosed Multiple myeloma (NDMM)- master-2 trial. Blood. 2024; 144:2000.1-2000.3.","DOI":"10.1182\/blood-2024-200210"},{"key":"4229_CR71","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1182\/blood.2024025746","volume":"145","author":"A Badros","year":"2025","unstructured":"Badros A, Foster L, Anderson LD Jr, Chaulagain CP, Pettijohn E, Cowan AJ, et al. Daratumumab with lenalidomide as maintenance after transplant in newly diagnosed multiple myeloma: the AURIGA study. Blood. 2025;145:300\u201310.","journal-title":"Blood."},{"key":"4229_CR72","doi-asserted-by":"publisher","first-page":"e422","DOI":"10.1016\/S2352-3026(21)00130-7","volume":"8","author":"B Diamond","year":"2021","unstructured":"Diamond B, Korde N, Lesokhin AM, Smith EL, Shah U, Mailankody S, et al. Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trial. Lancet Haematol. 2021;8:e422\u201332.","journal-title":"Lancet Haematol"},{"key":"4229_CR73","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-189022","volume":"142","author":"FB Askeland","year":"2023","unstructured":"Askeland FB, Rasmussen A-M, Lysen A, Hauk\u00e5s E, Eilertsen AL, Moksnes M, et al. Will survival improve by treating multiple myeloma patients at MRD relapse? the Remnant study. Blood. 2023;142:4755.","journal-title":"Blood"},{"key":"4229_CR74","unstructured":"GEM-TECTAL. Teclistamab-daratumumab and talquestamab-daratumumab in newly diagnosed high-risk multiple myeloma (GEM-TECTAL). 2023. Updated 19 March2025. Accessed 2 December 2025. https:\/\/www.clinicaltrials.gov\/study\/NCT05849610?term."},{"key":"4229_CR75","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","volume":"376","author":"M Attal","year":"2017","unstructured":"Attal M, Lauwers-Cances V, Hulin C, Leleu X, Caillot D, Escoffre M, et al. Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma. N Engl J Med. 2017;376:1311\u201320.","journal-title":"N Engl J Med"},{"key":"4229_CR76","doi-asserted-by":"publisher","first-page":"e374","DOI":"10.1016\/S1470-2045(24)00094-9","volume":"25","author":"Y Lin","year":"2024","unstructured":"Lin Y, Qiu L, Usmani S, Joo CW, Costa L, Derman B, et al. Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee. Lancet Oncol. 2024;25:e374\u201387.","journal-title":"Lancet Oncol"},{"key":"4229_CR77","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s41408-023-00820-y","volume":"13","author":"R Bansal","year":"2023","unstructured":"Bansal R, Baksh M, Larsen JT, Hathcock MA, Dingli D, Stewart AK, et al. Prognostic value of early bone marrow MRD status in CAR-T therapy for myeloma. Blood Cancer J. 2023;13:47.","journal-title":"Blood Cancer J"},{"key":"4229_CR78","doi-asserted-by":"publisher","first-page":"2218","DOI":"10.1182\/blood.2019002610","volume":"134","author":"L Sanoja-Flores","year":"2019","unstructured":"Sanoja-Flores L, Flores-Montero J, Puig N, Contreras-Sanfeliciano T, Pontes R, Corral-Mateos A, et al. Blood monitoring of circulating tumor plasma cells by next generation flow in multiple myeloma after therapy. Blood. 2019;134:2218\u201322.","journal-title":"Blood"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-026-04229-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-026-04229-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-026-04229-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T19:30:29Z","timestamp":1782847829000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-026-04229-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,28]]},"references-count":78,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["4229"],"URL":"https:\/\/doi.org\/10.1007\/s12185-026-04229-8","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,28]]},"assertion":[{"value":"5 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Takeshi Yoroidaka has received honoraria from Janssen Pharmaceuticals Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}